Motesanib

Drug Profile

Motesanib

Alternative Names: AMG-706; Motesanib diphosphate

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer Amgen; Takeda Bio Development Center
  • Class Amides; Antineoplastics; Indoles; Nicotinic-acids; Pyridines; Small molecules
  • Mechanism of Action Platelet-derived growth factor receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Thyroid cancer

Most Recent Events

  • 19 May 2015 Discontinued - Phase-III for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in Taiwan, South Korea, Hong Kong, Japan (PO)
  • 17 Feb 2015 Takeda Pharmaceuticals terminates the MONET-A phase III trial in Non-small cell lung cancer (advanced disease, combination therapy) in Japan, South Korea, Taiwan, Hong Kong
  • 01 Dec 2012 Amgen completes a phase II trial in Gastrointestinal stromal tumours in Japan (NCT00254267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top